Enhanced Multimodal Chromatography Method for HIV-1 Envelope Glycoprotein Purification

An improved multimodal chromatography method for purifying HIV-1 envelope glycoprotein, enhancing purification efficiency, and reducing protein aggregation through real-time monitoring and optimized purification conditions.

The original patent for multimodal chromatography method for purifying HIV-1 envelope glycoprotein has limitations in terms of purification efficiency and protein aggregation. The new inventive concept addresses these limitations by introducing real-time monitoring, optimized purification conditions, and novel multimodal resins to improve the overall purification process.

The new inventive concept comprises a system for purifying HIV-1 envelope glycoprotein using a multimodal chromatography column and a control unit configured to optimize purification conditions based on real-time monitoring of protein aggregation. The method involves capturing the protein on a multimodal resin and eluting the protein using a gradient of salt concentration and pH. The multimodal resin is designed with a polymer matrix and a ligand that selectively binds to the glycoprotein, wherein the ligand is a synthetic peptide derived from a CD4 receptor. The purification process can be further optimized using a combination of temperature and ionic strength gradients. The system also includes a sensor for detecting protein aggregation and a control unit configured to adjust purification conditions in response to the detected aggregation.

The new inventive concept introduces novel features such as real-time monitoring, optimized purification conditions, and a synthetic peptide-derived ligand, which are not present in the original patent. These features provide a significant improvement in purification efficiency and reduction in protein aggregation, making the new inventive concept non-obvious and novel compared to the original patent.

Alternative embodiments of the inventive concept include using different types of multimodal resins, varying the gradient conditions, and incorporating additional sensors for detecting protein aggregation. Variations of the system can also be designed for specific types of HIV-1 envelope glycoproteins, such as clade C or mosaic gp140 proteins.

The enhanced multimodal chromatography method has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the development of HIV vaccines and therapies. The improved purification efficiency and reduced protein aggregation can lead to higher yields and better quality of HIV-1 envelope glycoproteins, making it an attractive solution for companies involved in HIV research and development.